Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer

被引：0
|
作者：
Viale, G [1 ]
Regan, M [1 ]
Dell'Orto, P [1 ]
Del Curto, B [1 ]
Braye, S [1 ]
Orosz, Z [1 ]
Brown, R [1 ]
Olszewski, WP [1 ]
Knox, F [1 ]
Oehlschlegel, C [1 ]
Thürlimann, B [1 ]
机构：
[1] BIG 1 98 Collaborat Int Breast Canc Study Grp, Bern, Switzerland
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2005年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S13 / S14
页数：2
相关论文
共 50 条
  • [1] Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole versus tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer
    Viale, G.
    Regan, M.
    Dell'Orto, P.
    Curto, Del B.
    Braye, S.
    Orosz, Z.
    Brown, R.
    Olszewski, W. P.
    Knox, F.
    Oehlschlegel, C.
    Thurlimann, B.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 (03) : 339 - 339
  • [2] Central Review of ER, PgR and HER2 in BIG 1-98 Evaluating Letrozole vs. Letrozole Followed by Tamoxifen vs. Tamoxifen Followed by Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women with Hormone Receptor-Positive Breast Cancer
    Viale, G.
    Regan, M. M.
    Dell'Orto, P.
    Mastropasqua, M. G.
    Rasmussen, B. B.
    MacGrogan, G.
    Braye, S.
    Orosz, Z.
    Giobbie-Hurder, A.
    Neven, P.
    Knox, F.
    Oehlschlegel, C.
    Thuerlimann, B.
    Coates, A. S.
    Goldhirsch, A.
    CANCER RESEARCH, 2009, 69 (24) : 504S - 504S
  • [3] Central assessment of ER, PgR and HER2 in BIG 1-98 evaluating letrozole (L) compared to tamoxifen (T) as initial adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive breast cancer
    Rasmussen, B. B.
    Regan, M. M.
    Lykkesfeldt, A. E.
    Dell'Orto, P.
    Del Curto, B.
    Henriksen, K. L.
    Mastropasqua, M. G.
    Thurlimann, B.
    Viale, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] Letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Update of the BIG 1-98 primary core analysis
    Thuerlimann, B.
    BREAST, 2009, 18 : S60 - S60
  • [5] BIG 1-98: A randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer
    Mouridsen, H. T.
    Giobbie-Hurder, A.
    Mauriac, L.
    Paridaens, R.
    Colleoni, M.
    Thuerlimann, B.
    Forbes, J. F.
    Gelber, R. D.
    Wardley, A.
    Smith, I
    Price, K. N.
    Coates, A.
    Goldhirsch, A.
    CANCER RESEARCH, 2009, 69 (02) : 66S - 67S
  • [6] BIG 1-98: Randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer.
    Thurlimann, BJ
    Keshaviah, A
    Mouridsen, H
    Mauriac, L
    Forbes, JF
    Paridaens, R
    Castiglione-Gertsch, M
    Gelber, RD
    Smith, I
    Goldhirsch, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 6S - 6S
  • [7] BIG 1-98: A randomized double-blind phase III study comparing letrozole and tamoxifen given in sequence vs. alone as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer.
    Mouridsen, H. T.
    Keshaviah, A.
    Mauriac, L.
    Forbes, J.
    Paridaens, R.
    Castiglione-Gertsch, M.
    Gelber, R.
    Smith, I.
    Thuerlimann, B.
    Goldhirsch, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 10S - 10S
  • [8] DESIGN AND EVOLUTION OF BIG 1-98: A RANDOMIZED, DOUBLE-BLIND, PHASE-III STUDY COMPARING LETROZOLE AND TAMOXIFEN AS ADJUVANT ENDOCRINE THERAPY FOR POSTMENOPAUSAL WOMEN WITH RECEPTOR-POSITIVE, EARLY BREAST CANCER - BIG 1-98 COLLABORATIVE AND INTERNATIONAL BREAST CANCER STUDY GROUPS
    Giobbie-Hurder, A. E.
    Gelber, R. D.
    ANNALS OF ONCOLOGY, 2008, 19 : 80 - 80
  • [9] Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer
    Regan, Meredith M.
    Price, Karen N.
    Giobbie-Hurder, Anita
    Thuerlimann, Beat
    Gelber, Richard D.
    BREAST CANCER RESEARCH, 2011, 13 (03)
  • [10] Interpreting breast international group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer
    Meredith M Regan
    Karen N Price
    Anita Giobbie-Hurder
    Beat Thürlimann
    Richard D Gelber
    Breast Cancer Research, 13
12345